Published market data showed Pacific Biosciences of California (NASDAQ:PACB) falling 5.9% to USD 2.70 on October 6, 2026. The move came alongside weakness in other genomics and biotech names, including Guardant Health and Caribou Biosciences, which points to sector pressure rather than a company …
AMN Healthcare announced second quarter 2026 results on August 6, 2026. Revenue of USD 673.2 million rose 2% from a year earlier.Net Incomewas USD 21.2 million, or USD 0.53 per diluted share on aGAAPbasis, and adjustedDiluted Earnings per Sharewere USD 0.77. Adjusted EBITDA of …
Aveanna Healthcare Holdings announced second quarter results and revised 2026 guidance on August 13, 2026. Revenue of USD 670.5 million was up 13.7% from USD 589.6 million a year earlier. Net income was USD 40.3 million versus USD 27.0 million, and adjusted EBITDA grew …
On October 6, 2026 Crescent Biopharma (NASDAQ:CBIO) announced options to buy an aggregate 81,525 ordinary shares for six non-executive employees, approved October 5. The exercise price of USD 13.94 equals the October 5 closing price. The options run 10 years under the 2025 Employment …
Evolent Health (NYSE:EVH) rose about 6.1% to USD 4.07 on October 7, 2026, according to published market data. Claritev (NYSE:CTEV) gained 2.5%. Phreesia (NYSE:PHR) added 0.2%, a 1.4% median for the pair, so the move was larger than the group. We found no company …
Cencora's 50-day moving average of USD 317.90 has moved above its 200-day moving average of USD 317.82, completing a golden cross with a gap of 0.027 percent, a narrow but technically confirmed crossover. Shares recently traded at USD 319.69, up 1.05 percent, placing the …
Savara is approaching the FDA's November 22, 2026 target action date for MOLBREEVI, its inhaled therapy for autoimmune pulmonary alveolar proteinosis, under Priority Review following a three-month extension granted earlier in 2026. The drug carries Fast Track, Breakthrough Therapy andOrphan Drugdesignations, and Savara (NASDAQ:SVRA) …
Published market data show Picard Medical (NYSEAMERICAN:PMI) rising about 13.3% to USD 9.90, versus the 15.3% in some early reports. The exact session is uncertain: another quote page showed USD 8.67 at 1:47 p.m. ET on October 7, 2026, so the USD 9.90 level …
Progyny (NASDAQ:PGNY) issued a company release on October 7, 2026 titled as selling season pacing to a record level. It said 1.2 million new covered lives are expected from commitments to date and anticipated remaining decisions, with launches through the first half of 2027. …
Savara (NASDAQ:SVRA) rose about 7.6% to USD 5.01 on October 7, 2026, according to published market data, with some quote pages showing a gain near 8.0% around midday. Early reports tied the move to Citizens reiterating its rating on the Molbreevi launch outlook, which …